Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study).
Ting Li, Teng Zhou, Biyun Wang et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase II clinical trial evaluated adebrelimab, bevacizumab, and cisplatin or carboplatin in 35 patients with triple-negative breast cancer and active brain metastases. The confirmed CNS objective response rate was 77.1% (27/35, 95% CI, 59.9 to 89.6), and the CNS clinical benefit rate was 80.0% (28/35, 95% CI, 63.1 to 91.6). Median overall progression-free survival was 8.3 months, median CNS-PFS was 10.3 months, and median overall survival was 21.1 months. Grade ≥3 treatment-related adverse events occurred in 65.7% (23/35).
Key findings
- Confirmed CNS objective response rate was 77.1% (27/35, 95% CI, 59.9 to 89.6); CNS clinical benefit rate was 80.0% (28/35, 95% CI, 63.1 to 91.6).
- Median overall PFS was 8.3 months (95% CI, 5.8 to 11.5), median CNS-PFS was 10.3 months (95% CI, 7.4 to 14.3), and median OS was 21.1 months (95% CI, 13.2 to not reached).
- Grade ≥3 treatment-related adverse events occurred in 65.7% (23/35); treatment-related serious adverse events occurred in five patients (14.3%), with no treatment-related deaths.
Why it matters
Active brain metastases in triple-negative breast cancer are associated with poor outcomes and limited treatment options. The high observed intracranial response rate and reported CNS-PFS provide a signal of activity for this combination in a population with substantial unmet need. The frequency of severe treatment-related adverse events is also important when weighing the potential benefit and burden of further evaluation.
What to keep in mind
This was a phase II trial involving 35 patients; the abstract does not report a comparator group, so efficacy cannot be compared directly with other regimens.